Ziconotide

CI 1009, SNX 111

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Bowersox S, Tich N, Mayo M, et al. SNX-111. Drugs of the Future 1998 Feb; 23: 152–60
CAS Google Scholar
Luther RR, Sperzel WD, Valentino KL. Pharmacologic activity of SNX-111, the first N-type, neuron-specific, calcium channel blocker, is demonstrated in man. J Clin Pharmacol 1994 Oct; 34: 1014
Google Scholar
McGuire D, Kugler A, Bowersox S, et al. SNX-111: the first N-type, voltage-sensitive calcium channel antagonist administered to humans: pharmacokinetics and evidence of drug effect. Neurology 1996 Feb; 46 Suppl.: 203
Article Google Scholar
Piecoro LT, Wermeling D, Pfeifer B, et al. Intrathecal SNX-111: a novel peptide for treating malignant and neuropathic pain. Pharmacotherapy 1996 May–Jun; 16: 491
Google Scholar
Atanassoff PG, Hartmannsgruber MWB, Sturaitis M, et al. A new N-type calcium channel blocker SNX-111 administered intrathecally for acute postoperative pain. Br J Anaesth 1998 May; 80 Suppl. 1: 181
Google Scholar
Buchan AM, Gertler SZ, Li H, et al. A selective N-type Ca2+-channel blocker prevents CA1 injury 24h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cerebral Blood Flow Metab 1994 Nov; 14: 903–10
Article CAS Google Scholar
Zhao Q, Khansari P, Luther RR, et al. Neuroprotection by selective blockade of N-type neuronal calcium channels: evidence for a wide therapeutic window in focal cerebral ischaemia. 7th International Symposium on Pharmacology of Cerebral Ischemia: 1998 Jul 27; 73
Google Scholar

Ziconotide. Drugs R&D 1, 46–48 (1999). https://doi.org/10.2165/00126839-199901010-00019

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.